Mycosis fungoides history and symptoms: Difference between revisions
Jump to navigation
Jump to search
| (24 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Mycosis fungoides}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{S.G.}} | ||
==Overview== | ==Overview== | ||
The most common symptoms of | The most common [[Symptom|symptoms]] of mycosis fungoides include [[fever]], [[weight loss]], [[skin]] [[rash]], [[night sweats]], [[itching]], [[chest pain]], [[abdominal pain]], and [[bone pain]].<ref name="seer.cancer">Cutaneous T cell lymphoma. Surveillance, Epidemiology, and End Results . http://seer.cancer.gov/seertools/hemelymph/51f6cf56e3e27c3994bd52f7/ Accessed on January 19, 2016</ref> | ||
==History and Symptoms== | ==History and Symptoms== | ||
===History=== | ===History=== | ||
*The majority of patients with mycosis fungoides | *The majority of [[Patient|patients]] with mycosis fungoides is present with:<ref name="FossGirardi2017">{{cite journal|last1=Foss|first1=Francine M.|last2=Girardi|first2=Michael|title=Mycosis Fungoides and Sezary Syndrome|journal=Hematology/Oncology Clinics of North America|volume=31|issue=2|year=2017|pages=297–315|issn=08898588|doi=10.1016/j.hoc.2016.11.008}}</ref> | ||
**Skin patches and plaques | **[[Skin]] patches and [[Plaque|plaques]] | ||
**Skin erythema with or without exfoliation | **[[Skin]] [[erythema]] with or without [[exfoliation]] | ||
***Erythroderma observed patchy or diffuse<ref name="VonderheidBernengo2002" /> | ***[[Erythroderma]] observed patchy or [[diffuse]]<ref name="VonderheidBernengo2002" /> | ||
***Erythroderma observed with cracking or fissuring of the palms and soles.<ref name="VonderheidBernengo2002">{{cite journal|last1=Vonderheid|first1=Eric C.|last2=Bernengo|first2=Maria Grazia|last3=Burg|first3=Günter|last4=Duvic|first4=Madeleine|last5=Heald|first5=Peter|last6=Laroche|first6=Liliane|last7=Olsen|first7=Elise|last8=Pittelkow|first8=Mark|last9=Russell-Jones|first9=Robin|last10=Takigawa|first10=Masahiro|last11=Willemze|first11=Rein|title=Update on erythrodermic cutaneous T-cell lymphoma: Report of the international society for cutaneous lymphomas|journal=Journal of the American Academy of Dermatology|volume=46|issue=1|year=2002|pages=95–106|issn=01909622|doi=10.1067/mjd.2002.118538}}</ref> | ***[[Erythroderma]] observed with cracking or fissuring of the palms and soles.<ref name="VonderheidBernengo2002">{{cite journal|last1=Vonderheid|first1=Eric C.|last2=Bernengo|first2=Maria Grazia|last3=Burg|first3=Günter|last4=Duvic|first4=Madeleine|last5=Heald|first5=Peter|last6=Laroche|first6=Liliane|last7=Olsen|first7=Elise|last8=Pittelkow|first8=Mark|last9=Russell-Jones|first9=Robin|last10=Takigawa|first10=Masahiro|last11=Willemze|first11=Rein|title=Update on erythrodermic cutaneous T-cell lymphoma: Report of the international society for cutaneous lymphomas|journal=Journal of the American Academy of Dermatology|volume=46|issue=1|year=2002|pages=95–106|issn=01909622|doi=10.1067/mjd.2002.118538}}</ref> | ||
**Eczema | **[[Eczema]] | ||
**Psoriasis | **[[Psoriasis]] | ||
**Other benign skin disorders | **Other [[benign]] [[skin]] [[Disorder (medicine)|disorders]] | ||
*Patients with advanced disease may have a positive history of with cutaneous tumors or nodules or diffuse skin erythema with or without exfoliation. | *[[Patient|Patients]] with advanced [[disease]] may have a positive history of with cutaneous tumors or nodules or diffuse skin erythema with or without exfoliation. | ||
*Skin lesions in the disease obserevedc in non–sunexposed areas (bathing trunk distribution) and lesions may be hyperpigmented or hypopigmented, or may ulcerate. | *[[Skin]] [[Lesion|lesions]] in the [[disease]] obserevedc in non–sunexposed areas (bathing trunk distribution) and lesions may be hyperpigmented or hypopigmented, or may ulcerate. | ||
*Tumors | *[[Tumor|Tumors]] | ||
**> 1 cm in size (depth or vertical growth) | **> 1 cm in size (depth or vertical growth) | ||
Diagnosis criteria from the International Society for Cutaneous Lymphoma is: | Diagnosis criteria from the International Society for Cutaneous Lymphoma is:<ref name="FossGirardi2017" /><ref name="PimpinelliOlsen2005">{{cite journal|last1=Pimpinelli|first1=Nicola|last2=Olsen|first2=Elise A.|last3=Santucci|first3=Marco|last4=Vonderheid|first4=Eric|last5=Haeffner|first5=Andreas C.|last6=Stevens|first6=Seth|last7=Burg|first7=Guenter|last8=Cerroni|first8=Lorenzo|last9=Dreno|first9=Brigitte|last10=Glusac|first10=Earl|last11=Guitart|first11=Joan|last12=Heald|first12=Peter W.|last13=Kempf|first13=Werner|last14=Knobler|first14=Robert|last15=Lessin|first15=Stuart|last16=Sander|first16=Christian|last17=Smoller|first17=Bruce S.|last18=Telang|first18=Gladys|last19=Whittaker|first19=Sean|last20=Iwatsuki|first20=Keiji|last21=Obitz|first21=Erik|last22=Takigawa|first22=Masahiro|last23=Turner|first23=Maria L.|last24=Wood|first24=Gary S.|title=Defining early mycosis fungoides|journal=Journal of the American Academy of Dermatology|volume=53|issue=6|year=2005|pages=1053–1063|issn=01909622|doi=10.1016/j.jaad.2005.08.057}}</ref> | ||
{| class="wikitable" | {| class="wikitable" | ||
|+ | |+ | ||
!Criteria | ! style="background: #4479BA; color:#FFF;" |Criteria | ||
!Major( 2pinots) | ! style="background: #4479BA; color:#FFF;" |Major( 2pinots) | ||
!Minor(1point) | ! style="background: #4479BA; color:#FFF;" |Minor(1point) | ||
|- | |- | ||
|'''Persistent and/or progressive patches and plaques plus''' | |'''Persistent and/or progressive patches and plaques plus''' | ||
|Any 2 | |Any 2 | ||
|Any 1 | |Any 1 | ||
|- | |||
| colspan="3" style="background: #B0C4DE; color:#FFF;" ! |Clinical | |||
|- | |- | ||
|1. Non–sun-exposed location | |1. Non–sun-exposed location | ||
| Line 43: | Line 46: | ||
| | | | ||
|- | |- | ||
| colspan="3" |'''Histopathologic''' | | colspan="3" style="background: #B0C4DE; color:#FFF;" ! |'''Histopathologic''' | ||
|- | |- | ||
|Superficial lymphoid infiltrate plus | |Superficial lymphoid infiltrate plus | ||
| Line 52: | Line 55: | ||
| | | | ||
| | | | ||
|- | |- | ||
|2. Atypia | |2. Atypia | ||
| | | | ||
| | | | ||
|- | |||
| colspan="3" style="background: #B0C4DE; color:#FFF;" ! |'''Molecular/biological''' | |||
|- | |- | ||
|Clonal TCR gene rearrangement | |Clonal TCR gene rearrangement | ||
| | | | ||
| | |Present | ||
|- | |- | ||
|'''Immunopathologic''' | | colspan="3" style="background: #B0C4DE; color:#FFF;" ! |'''Immunopathologic''' | ||
|- | |- | ||
|1. CD2, CD3, CD5 in <59% of T cells | |1. CD2, CD3, CD5 in <59% of T cells | ||
| | | | ||
| | |Any 1 | ||
|- | |- | ||
|2. CD7 in <10% of T cells | |2. CD7 in <10% of T cells | ||
Latest revision as of 17:54, 12 February 2019
|
Mycosis fungoides Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mycosis fungoides history and symptoms On the Web |
|
American Roentgen Ray Society Images of Mycosis fungoides history and symptoms |
|
Risk calculators and risk factors for Mycosis fungoides history and symptoms |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
The most common symptoms of mycosis fungoides include fever, weight loss, skin rash, night sweats, itching, chest pain, abdominal pain, and bone pain.[1]
History and Symptoms
History
- The majority of patients with mycosis fungoides is present with:[2]
- Skin patches and plaques
- Skin erythema with or without exfoliation
- Erythroderma observed patchy or diffuse[3]
- Erythroderma observed with cracking or fissuring of the palms and soles.[3]
- Eczema
- Psoriasis
- Other benign skin disorders
- Patients with advanced disease may have a positive history of with cutaneous tumors or nodules or diffuse skin erythema with or without exfoliation.
- Skin lesions in the disease obserevedc in non–sunexposed areas (bathing trunk distribution) and lesions may be hyperpigmented or hypopigmented, or may ulcerate.
- Tumors
- > 1 cm in size (depth or vertical growth)
Diagnosis criteria from the International Society for Cutaneous Lymphoma is:[2][4]
| Criteria | Major( 2pinots) | Minor(1point) |
|---|---|---|
| Persistent and/or progressive patches and plaques plus | Any 2 | Any 1 |
| Clinical | ||
| 1. Non–sun-exposed location | ||
| 2.Size/shape variation | ||
| 3.Poikiloderma | ||
| Histopathologic | ||
| Superficial lymphoid infiltrate plus | Both | Either |
| 1. Epidermotropism | ||
| 2. Atypia | ||
| Molecular/biological | ||
| Clonal TCR gene rearrangement | Present | |
| Immunopathologic | ||
| 1. CD2, CD3, CD5 in <59% of T cells | Any 1 | |
| 2. CD7 in <10% of T cells | ||
| 3. Epidermal discordance from expression of CD2, CD3, CD5, and CD7 on dermal T cells | ||
Common Symptoms
Symptoms of cutaneous T cell lymphoma include:[1]
References
- ↑ 1.0 1.1 Cutaneous T cell lymphoma. Surveillance, Epidemiology, and End Results . http://seer.cancer.gov/seertools/hemelymph/51f6cf56e3e27c3994bd52f7/ Accessed on January 19, 2016
- ↑ 2.0 2.1 Foss, Francine M.; Girardi, Michael (2017). "Mycosis Fungoides and Sezary Syndrome". Hematology/Oncology Clinics of North America. 31 (2): 297–315. doi:10.1016/j.hoc.2016.11.008. ISSN 0889-8588.
- ↑ 3.0 3.1 Vonderheid, Eric C.; Bernengo, Maria Grazia; Burg, Günter; Duvic, Madeleine; Heald, Peter; Laroche, Liliane; Olsen, Elise; Pittelkow, Mark; Russell-Jones, Robin; Takigawa, Masahiro; Willemze, Rein (2002). "Update on erythrodermic cutaneous T-cell lymphoma: Report of the international society for cutaneous lymphomas". Journal of the American Academy of Dermatology. 46 (1): 95–106. doi:10.1067/mjd.2002.118538. ISSN 0190-9622.
- ↑ Pimpinelli, Nicola; Olsen, Elise A.; Santucci, Marco; Vonderheid, Eric; Haeffner, Andreas C.; Stevens, Seth; Burg, Guenter; Cerroni, Lorenzo; Dreno, Brigitte; Glusac, Earl; Guitart, Joan; Heald, Peter W.; Kempf, Werner; Knobler, Robert; Lessin, Stuart; Sander, Christian; Smoller, Bruce S.; Telang, Gladys; Whittaker, Sean; Iwatsuki, Keiji; Obitz, Erik; Takigawa, Masahiro; Turner, Maria L.; Wood, Gary S. (2005). "Defining early mycosis fungoides". Journal of the American Academy of Dermatology. 53 (6): 1053–1063. doi:10.1016/j.jaad.2005.08.057. ISSN 0190-9622.